Major transition in cancer care is underway, where much more will be expected of cancer therapies and factored into care paths.

In Economic and clinical value: the future of cancer care, President Rita Numerof, Ph.D. discusses the major changes occurring in the cancer care landscape.  Pharmaceutical companies will need to focus on evidence based care, patient reported outcomes, supportive care, cost and new payment models.